293 related articles for article (PubMed ID: 24866478)
1. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459.
Pettipher R; Hunter MG; Perkins CM; Collins LP; Lewis T; Baillet M; Steiner J; Bell J; Payton MA
Allergy; 2014 Sep; 69(9):1223-32. PubMed ID: 24866478
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma.
Barnes N; Pavord I; Chuchalin A; Bell J; Hunter M; Lewis T; Parker D; Payton M; Collins LP; Pettipher R; Steiner J; Perkins CM
Clin Exp Allergy; 2012 Jan; 42(1):38-48. PubMed ID: 21762224
[TBL] [Abstract][Full Text] [Related]
3. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis.
Straumann A; Hoesli S; Bussmann Ch; Stuck M; Perkins M; Collins LP; Payton M; Pettipher R; Hunter M; Steiner J; Simon HU
Allergy; 2013 Mar; 68(3):375-85. PubMed ID: 23379537
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459.
Singh D; Cadden P; Hunter M; Pearce Collins L; Perkins M; Pettipher R; Townsend E; Vinall S; O'Connor B
Eur Respir J; 2013 Jan; 41(1):46-52. PubMed ID: 22496329
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
[TBL] [Abstract][Full Text] [Related]
6. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
Gonem S; Berair R; Singapuri A; Hartley R; Laurencin MFM; Bacher G; Holzhauer B; Bourne M; Mistry V; Pavord ID; Mansur AH; Wardlaw AJ; Siddiqui SH; Kay RA; Brightling CE
Lancet Respir Med; 2016 Sep; 4(9):699-707. PubMed ID: 27503237
[TBL] [Abstract][Full Text] [Related]
7. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial.
Horak F; Zieglmayer P; Zieglmayer R; Lemell P; Collins LP; Hunter MG; Steiner J; Lewis T; Payton MA; Perkins CM; Pettipher R
Allergy; 2012 Dec; 67(12):1572-9. PubMed ID: 23025511
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment.
Hall IP; Fowler AV; Gupta A; Tetzlaff K; Nivens MC; Sarno M; Finnigan HA; Bateman ED; Rand Sutherland E
Pulm Pharmacol Ther; 2015 Jun; 32():37-44. PubMed ID: 25861737
[TBL] [Abstract][Full Text] [Related]
9. The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.
Erpenbeck VJ; Popov TA; Miller D; Weinstein SF; Spector S; Magnusson B; Osuntokun W; Goldsmith P; Weiss M; Beier J
Pulm Pharmacol Ther; 2016 Aug; 39():54-63. PubMed ID: 27354118
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.
Busse WW; Wenzel SE; Meltzer EO; Kerwin EM; Liu MC; Zhang N; Chon Y; Budelsky AL; Lin J; Lin SL
J Allergy Clin Immunol; 2013 Feb; 131(2):339-45. PubMed ID: 23174659
[TBL] [Abstract][Full Text] [Related]
11. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
[TBL] [Abstract][Full Text] [Related]
12. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics.
Diamant Z; Sidharta PN; Singh D; O'Connor BJ; Zuiker R; Leaker BR; Silkey M; Dingemanse J
Clin Exp Allergy; 2014 Aug; 44(8):1044-52. PubMed ID: 24964348
[TBL] [Abstract][Full Text] [Related]
13. Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma.
Kuna P; Bjermer L; Tornling G
Drug Des Devel Ther; 2016; 10():2759-70. PubMed ID: 27621597
[TBL] [Abstract][Full Text] [Related]
14. Fevipiprant, an oral prostaglandin DP
Bateman ED; Guerreros AG; Brockhaus F; Holzhauer B; Pethe A; Kay RA; Townley RG
Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28838980
[TBL] [Abstract][Full Text] [Related]
15. A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma.
Miller D; Wood C; Bateman E; LaForce C; Blatchford J; Hilbert J; Gupta A; Fowler A
Allergy Asthma Proc; 2017 Mar; 38(2):157-164. PubMed ID: 28234053
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of oral montelukast added to standard therapy for acute asthma exacerbations in children aged 6 to 14 years.
Nelson KA; Smith SR; Trinkaus K; Jaffe DM
Pediatr Emerg Care; 2008 Jan; 24(1):21-7. PubMed ID: 18165796
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β
Bateman ED; O'Brien C; Rugman P; Luke S; Ivanov S; Uddin M
Drug Des Devel Ther; 2018; 12():1093-1106. PubMed ID: 29765200
[TBL] [Abstract][Full Text] [Related]
18. Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75%.
Becker A; Swern A; Tozzi CA; Yu Q; Reiss T; Knorr B
Curr Med Res Opin; 2004 Oct; 20(10):1651-9. PubMed ID: 15462699
[TBL] [Abstract][Full Text] [Related]
19. Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial).
Bjermer L; Bisgaard H; Bousquet J; Fabbri LM; Greening A; Haahtela T; Holgate ST; Picado C; Leff JA
Respir Med; 2000 Jun; 94(6):612-21. PubMed ID: 10921768
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma.
Ortega H; Fitzgerald M; Raghupathi K; Tompkins CA; Shen J; Dittrich K; Pattwell C; Singh D
Clin Exp Allergy; 2020 Feb; 50(2):189-197. PubMed ID: 31659803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
